The Conversation (0)
RedHill Biopharma Announces Phase IIa 48-Week Final Results for RHB-104 in Multiple Sclerosis
Dec. 12, 2016 08:16AM PST
Pharmaceutical Investing
RedHill Biopharma today announces new data in its phase IIa trial investigating oral dose RHB-104 as a treatment for relapsing-remitting multiple sclerosis.
RedHill Biopharma (NASDAQ:RDHL) (TASE:RDHL) today announces new data in its phase IIa trial investigating oral dose RHB-104 as a treatment for relapsing-remitting multiple sclerosis.
According to the press release:
“Top-line final (48 weeks) results are consistent with the previously announced interim results suggesting meaningful positive safety and clinical signals upon 24 weeks of treatment with RHB-104 as an add-on therapy and support further clinical development.”
Dr. Ira Kalfus, Medical Director of RedHill, said the following:
“Although designed as an exploratory proof-of-concept study in a very small patient population and not powered for efficacy, the study results demonstrate positive safety data and clinical signals, supporting additional studies to better investigate the therapeutic potential of RHB-104 in RRMS.”